The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study

Conclusions: We demonstrate a higher prevalence of dyslipidemia preceding a diagnosis of CLL compared with control subjects, supporting preclinical data. Lipid-lowering medications appear to confer a survival advantage in CLL. Prospective studies are needed to confirm these results and test their potential as therapeutic applications.

Source: JNCI - October 19, 2016 Category: Cancer & Oncology Authors: Mozessohn, L., Earle, C., Spaner, D., Cheng, S. Y., Kumar, M., Buckstein, R. Tags: Article Source Type: research